PD1/PD-L1 inhibition as a potential radiosensitizer in head and neck squamous cell carcinoma: a case report

Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial

(2016) Tanguy Y Seiwert et al.   LANCET ONCOLOGY

Radiotherapy combined with immune checkpoint blockade immunotherapy: Achievements and challenges

(2015) Feifei Teng et al.   CANCER LETTERS

Irradiation and anti–PD-L1 treatment synergistically promote antitumor immunity in mice

(2014) Liufu Deng et al.   JOURNAL OF CLINICAL INVESTIGATION

Combining Radiation and Immunotherapy: A New Systemic Therapy for Solid Tumors?

(2014) C. Tang et al.   Cancer Immunology Research

Concurrent Radiotherapy and Ipilimumab Immunotherapy for Patients with Melanoma

(2013) C. A. Barker et al.   Cancer Immunology Research

An Abscopal Response to Radiation and Ipilimumab in a Patient with Metastatic Non-Small Cell Lung Cancer

(2013) E. B. Golden et al.   Cancer Immunology Research

Immunologic Correlates of the Abscopal Effect in a Patient with Melanoma

(2012) Michael A. Postow et al.   NEW ENGLAND JOURNAL OF MEDICINE